In 15 @entity1 (8 @entity1 , 7 @entity1 ), aged 44-81 years, with idiopathic @entity304 , the effects of @entity4087 ( @entity4087 ) were observed for up to 3 years. Of these @entity1 , four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six @entity1 had been on levodopa/decarboxylase inhibitor and @entity2847 for a period of 7.5 years. @entity4087 proved to be effective in all three groups of @entity1 and for each main symptom of the disease. @entity2003 and @entity400 showed a better response than @entity910 . A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years @entity1 were slightly better off than before the introduction of @entity4087 . Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. @entity4087 was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by @entity1 themselves, had shown very small or no improvement at the beginning of @entity4087 administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were @entity1833 and @entity910 . @entity551 did not prove a problem. @entity910 were not seen during monotherapy with @entity4087 in de novo @entity1 .

Three-year observation of XXXX ( @entity4087 ) in advanced and newly treated @entity304 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine'] @entity2003 :: ('MESH:D009127', 'Disease') :: ['Rigidity'] @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism'] @entity910 :: ('MESH:D004409', 'Disease') :: ['Dyskinesias', 'dyskinesias', 'akinesia'] @entity4087 :: ('MESH:C031649', 'Chemical') :: ['CU 32-085', 'mesulergine', 'Mesulergine'] @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity551 :: ('MESH:D007022', 'Disease') :: ['Orthostatic hypotension']
@entity4087 :: (MESH:C031649,Chemical) :: ['mesulergine']
